What They Told The Board
“We have a pipeline problem – we need more of it.”
Their CRO had been saying this for three quarters. The board believed it because the math looked simple: if win rate is 11% and target is $2M/quarter, you need $18M in pipeline. They had $8.4M. Gap identified. Solution obvious. Hire more SDRs. Run more sequences. Fill the top.
They’d already hired four.
What I Actually Saw
I spent the first week in their CRM. Not in dashboards – in deals. Reading notes. Pulling call recordings. Mapping stage progression.
Here’s what the pipeline actually looked like:
62% of Stage 2+ deals had no documented access to a decision-maker. Reps had talked to a champion – someone who liked the product – and called that “multi-threaded.” It wasn’t. It was single-threaded to someone without a signature.
The average deal had been in pipeline for 147 days. Not because the sales cycle was long. Because dead deals weren’t dead. They were sitting in Stage 3 and Stage 4 with last activity dates from two months prior, being dragged forward in every forecast call because removing them meant admitting the quarter was short.
Their top rep – the one carrying 43% of closed revenue – was doing something nobody had noticed. She was disqualifying twice as many deals as her peers. Her pipeline was half the size. Her win rate was 34%.
The company didn’t have a pipeline problem. It had a pipeline honesty problem. And the response – more top-of-funnel – was the equivalent of pouring water into a bucket with no bottom and blaming the faucet.
The Diagnosis
Three things were broken, and they were all connected.
First, qualification was binary. A deal was either “in pipeline” or “not in pipeline.” There was no mechanism to assess whether the deal was real – whether the buyer had acknowledged a problem severe enough to act on, whether the cost of doing nothing had been quantified, whether there was an external forcing function creating urgency. Deals entered the pipeline when a prospect agreed to a second meeting. That was the bar.
Second, stage progression was activity-based. A deal moved from Stage 2 to Stage 3 when the rep sent a proposal. Not when the buyer agreed on the scope of the problem. Not when stakeholders aligned. When the rep completed a task. The pipeline stages measured seller effort, not buyer commitment.
Third, forecast calls were theater. Every Monday, the VP of Sales asked each rep to “walk their deals.” Reps narrated optimistic stories. The VP nodded or pushed. Nobody asked the one question that mattered: What has the buyer agreed to that they hadn’t agreed to last week? If nothing – the deal hasn’t moved. Regardless of what stage it’s sitting in.
The result was a pipeline that looked like $8.4M but was probably worth $2M. Which meant their actual pipeline coverage wasn’t 4.2x. It was closer to 1x. Which meant they weren’t behind on pipeline generation. They were behind on pipeline truth.
What We Installed
I’m not going to walk through the full implementation – that’s client work and it’s specific to their team, their market, and their maturity. But the structural shifts matter because they illustrate a principle.
We replaced the binary qualification gate with a continuous health model. Every deal in pipeline was scored against four elements that had to be present – and stay present – for the deal to remain qualified. Not a one-time checklist at entry. A living monitor that could degrade. A deal that looked healthy in Week 2 could go yellow in Week 6 if conditions changed. And when it went yellow, it triggered a specific response – not a “check in,” but a diagnostic action.
We redefined what stage progression meant. Stages stopped being about what the rep did and started being about what the buyer agreed to. Moving from Stage 2 to Stage 3 required a specific buyer commitment – documented, not assumed. This cut their Stage 2+ pipeline by 40% in the first two weeks. That felt like a catastrophe. It was actually the first honest forecast they’d had in a year.
We killed the Monday forecast theater. Replaced it with a weekly pipeline review structured around one question per deal: What is the buyer’s next agreement, and what’s the evidence it will happen? If the rep couldn’t answer that, the deal got flagged – not for removal, but for diagnosis. Maybe it was saveable. But it needed a different conversation than “I’ll follow up next week.”
The Numbers, 90 Days Later
Pipeline shrank from $8.4M to $5.1M. The board was uncomfortable for about six weeks.
Then Q3 closed at $2.4M against a $2M target – the first clean beat in four quarters. Win rate on qualified pipeline was 31%. The top rep was no longer an anomaly. Two other reps had adopted the same disqualification discipline and were tracking at 26% and 28%.
The most important number wasn’t revenue. It was forecast accuracy. It went from 58% to 84%. Which meant the board could plan. Which meant the CEO stopped sandbagging with investors. Which meant the Series D conversation started from a position of credibility instead of hope.
The Principle
More pipeline is almost never the answer. More honest pipeline is almost always the answer.
When you pour resources into filling a pipeline that has no integrity – no real qualification, no buyer-verified consequences, no continuous health monitoring – you get exactly what this company had. Big numbers that feel good in a board deck and fall apart in a forecast.
The hardest conversation I have with every new client is the same one: your pipeline is going to shrink before it grows. That shrinkage isn’t a problem. It’s the diagnosis working.
I help B2B companies fix the revenue systems that legacy methodologies broke. If something in this post made you uncomfortable, it was probably the part that's true. Stop the bleeding.
